Abbreviations: ANOVA, analysis of variance; BL, a vaccine consisting of baculovirus and a tumor cell lysate; BLP, a vaccine consisting of baculovirus, a tumor cell lysate, and a CTL epitope peptide; BP, a vaccine consisting of baculovirus and a CTL epitope peptide; CTL, CD8 C cytotoxic T lymphocyte; DCs, dendritic cells; FITC, fluorescein isothiocyanate; IFA, incomplete Freund's adjuvant; IFNg, interferon gamma; IL, interleukin; mAb, monoclonal antibody; PBS, phosphate-buffered saline; PE, phycoerythrin; pfu, plaque-forming units; SD, standard deviation; TLR, toll-like receptor; T reg , regulatory T.To develop a potent cancer vaccine, it is important to study how to prepare highly immunogenic antigens and to identify the most appropriate adjuvants for the antigens. Here we show that a tumor lysate works as an effective antigen to prime CD4 C T-cell help when baculovirus is employed as an adjuvant. When immunized intradermally with the combination (BLP) of baculovirus, a CT26 tumor lysate, and a cytotoxic T-cell epitope peptide before a tumor challenge, 60% of mice rejected tumors. In contrast, all mice vaccinated with baculovirus plus a tumor lysate (BL) developed tumors. In addition, flow cytometry showed that tumor-specific, interferon g-producing CD8C cytotoxic T lymphocytes (CTLs) were robustly activated by intradermal immunization with BLP. When BLP was administered therapeutically to tumor-bearing mice, antitumor efficacy was better compared to BL. The established tumor was completely eradicated in 50-60% of BLP-treated mice, and induction of tumor-specific CTLs was observed, suggesting that the antitumor efficacy of BLP is mediated by CD8 C T cells. Numerous CD4 C T cells infiltrated the tumors of BLPtreated mice, whereas the antitumor effect of BLP almost disappeared after removal of the tumor lysate from BLP or after depletion of BLP-immunized mice of CD4 C T cells. Thus, the combination of a peptide, lysate, and baculovirus provides stronger antitumor immunity than does a peptide plus baculovirus or a lysate plus baculovirus; effectiveness of BLP is determined by functioning of CD4 C T cells stimulated with a tumor lysate.